Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 1.00 |
| ▸ | RAB9A | P51151 | 11/20 | 1.00 |
| ▸ | PKM | P14618 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.59 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | METAP2 | P50579 | 1/20 | 0.57 |
| ▸ | METAP1 | P53582 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29074212 | 0.87 | NPC1 (0.76) | NPC1RAB9APKMSMN1; SMN2MEN1 | |
| SCHEMBL31207080 | 0.83 | RAB9A (0.70) | NPC1RAB9APKMSMN1; SMN2MEN1 | |
| SCHEMBL2594378 | 0.82 | NPC1 (0.69) | NPC1RAB9APKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL1270133 | 0.81 | SMN1; SMN2 (0.75) | NPC1RAB9APKMSMN1; SMN2MEN1 | |
| SCHEMBL1528552 | 0.80 | NPC1 (0.66) | NPC1RAB9APKMSMN1; SMN2MEN1 | |
| SCHEMBL12309919 | 0.80 | NPC1 (0.66) | NPC1RAB9APKMSMN1; SMN2KMT2A | |
| SCHEMBL24074066 | 0.79 | SMN1; SMN2 (0.72) | NPC1RAB9APKMSMN1; SMN2MEN1 | |
| SCHEMBL6251182 | 0.79 | KDR (0.74) | NPC1RAB9APKMSMN1; SMN2LMNA | |
| SCHEMBL31707000 | 0.79 | NPC1 (0.66) | NPC1RAB9APKMSMN1; SMN2MEN1 | |
| SCHEMBL21511019 | 0.79 | SMN1; SMN2 (0.66) | NPC1RAB9APKMSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110213000-A1 | N-(2-THIAZOLYL)-AMIDE DERIVATIVES FOR THE TREATMENT OF OBESITY, DIABETES AND CARDIOVASCULAR DISEASES | ZELTIA, S.A. (ES) | 2011-09-01 | — | — | US | disclosed |
| EP-2020232-A1 | N-(1-thiazolyl)-amide derivatives for the treatment of obesity, diabetes and cardiovascular diseases | Zeltia, S.A. (ES) | 2009-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213000-A1 | N-(2-THIAZOLYL)-AMIDE DERIVATIVES FOR THE TREATMENT OF OBESITY, DIABETES AND CARDIOVASCULAR DISEASES | ADIPOR1, ADIPOR2, FABP4 | NPC1 649/4885RAB9A 3230/4885PKM 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.